**ESP VALIDATION GUIDANCE**

**Document Version 1.0**

**Prepared by the Massachusetts Department of Public Health and the Department of Population Medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute on behalf of the Massachusetts Department of Public Health.**

esphealth@harvardpilgrim.org

**April 26, 2018**

**Modification History**

|  |  |  |  |
| --- | --- | --- | --- |
| **Version** | **Date** | **Modification** | **By** |
| 1.0 | 4/26/2018 | * Original circulated version
 | MDPH/DPM |

*Intent:* Provide general guidance for performing a validation of cases identified by ESP, which is an onboarding requirement for the MDPH health information reporting portal (HIRP). The full process of validation occurs for each ESP algorithm implemented at a new site; at a minimum, data element validation and review of live data in a certification environment must occur when changes are made to existing algorithms. This document provides examples of frequently encountered issues and root causes, as identified by past validations. It is emphasized that this document be used only as a guide because it is by nature not exhaustive. Note that table templates for methodically documenting review findings have also been included. This document provides detail to be used in conjunction with the ESP Implementation Roadmap.

**SECTION 1: GUIDANCE FOR PERFORMING VALIDATION**

1. **Validation of ESP Detection Algorithm against Site’s EMR** (Step 3 in the ESP Implementation Roadmap)

*This validation is performed by the implementing clinical site in collaboration with Commonwealth Informatics, Inc. (CII) and the Massachusetts Department of Public Health (MDPH).*

1. Were there any cases identified by ESP that were not cases that should be reported to MDPH?
	1. Is a lab test/result mapped incorrectly in ESP?
	2. [HIV-specific]: was the case receiving PEP or PrEP? Was this treatment atypical (e.g., receiving PEP several times over a short period)?
	3. Another reason?
2. Were there any cases that should be reported to MDPH that ESP did not identify?
	1. Is a lab mapped incorrectly?
	2. Was there information that was not available to ESP?
		1. Was the case diagnosed somewhere else and this documented in their EMR as a note?
		2. Were labs done somewhere else and not accessible to ESP?
		3. Was the case treated somewhere else and prescribed medications not accessible to ESP?
3. Were there cases that were identified by ESP and would be reported to MDPH, but did not match predefined classifications (e.g., acute vs. chronic, active vs. latent)?
	1. Was the information required to make this distinction not available to ESP?
		1. Was there information contained in a note within the EMR that was not accessible to ESP?
		2. Were labs done somewhere else and not visible to ESP?
4. **Validation of ESP cases against MAVEN** (Step 4 in the ESP Implementation Roadmap)

*This validation is performed by MDPH staff in collaboration with the implementing clinical site. MDPH staff may ask for paper copies of extracts from the original case report for the final stages of content validation.*

1. Were there any cases identified by ESP that were not reported to MDPH? If so, work with the site to determine if the identified case truly has the condition of interest.
	1. If it is a real case, why wasn’t it reported to MDPH?
		1. Is a lab mapped incorrectly in ESP or HIRP?
		2. Was there an issue with ELR transmission?
		3. Was the case not reported by clinician?
		4. Another reason?
	2. If it is *not* a real case (i.e., false positive), what caused the case to be identified by ESP?
		1. Is a lab mapped incorrectly?
		2. Can a small adjustment be made to the algorithm to avoid this type of false positive?
		3. If not, can these false positives be identified and triaged in MAVEN?
		4. Is the number of false positives acceptable to MDPH?
2. Were there any cases reported to MDPH that were not identified by ESP? If so, work with the site to determine why.
	1. Is a lab incorrectly mapped?
	2. Was there information that was not available to ESP?
		1. Was the case diagnosed somewhere else and this documented in their EMR as a note?
		2. Were labs done somewhere else and not visible to ESP?
	3. Can a small adjustment be made to the algorithm to capture these cases that could be considered in future versions of the algorithm?
3. Were there cases that were identified by ESP and reported to MDPH, but revoked in MAVEN?
	1. Why was the case(s) revoked?
		1. Was the case(s) out of state?
	2. Could this information have been utilized by ESP to avoid sending the case(s) or to provide information to help determine if the case(s) should be revoked?
4. Were there cases that were identified by ESP and reported to MDPH, but did not match MAVEN classifications (e.g., acute vs. chronic, active vs. latent)?
	1. Was there information available to ESP (e.g., prior labs, diagnoses, medications) that were not reported to MAVEN, preventing MDPH from making the correct classification?
	2. Was the information required to make this distinction not available to ESP?
		1. Was there information in a note in the EMR that was not accessible to ESP?
		2. Were labs done somewhere else and not visible to ESP?
	3. Is a diagnosis code being used inappropriately/unexpectedly at a site?
	4. Could there have been an issue with a MAVEN workflow causing it to miss cases? For example, during previous validation of a disease, some cases were not being pulled into a workflow because MAVEN was searching for “YES” and not “Yes.”
5. **HL7 Message Validation** (Step 5 of the ESP Implementation Roadmap)

*This validation is performed by MDPH staff in collaboration with the implementing clinical site.*

1. Can the implementing site successfully send a message via SOAPxmitter to the Staging HIRP?
2. Does the message meet the requirements laid out in the ELR\_HL7\_231\_Implementation\_Guide\_ (supplied by MDPH staff)?
3. Is all mapping in the HIRP complete? This will include
	1. Laboratory tests/results for all relevant organisms
	2. Susceptibility information, with Abnormal flags
	3. Specimen source codes
	4. Race and ethnicity
	5. Result status
	6. Report status code
	7. All relevant mappings completed under the Organism = Miscellaneous tab (treatment, treatment date, symptoms, symptom date, etc.)
4. Do HL7 messages create errors in the HIRP staging site?
	1. MDPH staff work through syntax errors with the clinical site until messages no longer create errors
5. Were all the expected fields populated in the HL7 messages?
6. Can messages be successfully batched? (MDPH expects one batch per day. Multiple batches may be accepted, but not in real-time.)
7. Can batches be successfully sent even if there are no messages for a particular day i.e. can the system successfully generate empty batches?
8. Initial testing will take place with fake data; has live data been sent to the Staging HIRP?
9. When uploading a case to the MAVEN testing environment:
	1. Was the appropriate event created (as opposed to an unknown event)?
	2. Are the question packages being updated appropriately? Is the update where you’d expect it to be?
	3. Are there variables being reported in the HL7 messages that are not or only partially captured in MAVEN but should be?
	4. Are any fields repeating reported information?
	5. Are any fields being inappropriately overwritten in MAVEN?
	6. Are updates appending to existing cases appropriately?

**SECTION 2: GUIDANCE FOR DOCUMENTING VALIDATION FINDINGS**

1. **Documentation for validation of ESP cases against site’s EMR**

*Documentation is completed by the implementing clinical site.*

* 1. Create a Patient-Level Line List
1. Information that may be helpful to include
2. Reference IDs
	1. ESP ID
	2. Patient ID from site’s EMR
3. Date of case identification
4. Reason case was identified in ESP (which criteria did they meet?), if relevant
5. Classification as confirmed by EMR (i.e., acute vs. chronic, active vs. latent), if relevant
6. Notes learned about a case during validation
7. Example of what this table might look like:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Case Status** | **ESP ID** | **Pat ID** | **Date Identified** | **ESP Criteria** | **Notes**  |
| Identified by ESP and is a confirmed case | 1234 | 9101 | 1/1/2017 | A | N/A |
| Identified by ESP, but not a case | 1112 | 1516 | 1/2/2017 | B | Lab was mapped incorrectly in ESP. Mapping was fixed and case would no longer be identified by ESP. |
| Confirmed case, but not identified by ESP | N/A | 2728 | 1/6/2017 | A | Note in EMR states... Confirmatory lab was done prior to being seen at our site, so not in ESP.  |
| Acute in ESP, but confirmed chronic in EMR | 2930 | 3334 | 1/15/2017 | C | Note in EMR states... |
| Chronic in ESP, but confirmed acute in EMR | 3536 | 3940 | 1/20/2017 | D | Note in EMR states... |

* 1. Create a Validation Summary
1. Using the patient-level line list, put together a summary of findings from the validation to share with MDPH staff.
2. The following information should be included in a summary report for MDPH.
3. Number of cases identified
4. Time period in which cases were identified
5. Number of cases identified by ESP that should be reported to MDPH (i.e., “true positives”)
6. Number of cases identified by ESP that should not be reported to MDPH (i.e., “false positives”)
	1. Include reasons why cases were identified by ESP
7. Number of cases not identified by ESP that should be reported to MDPH (i.e., “false negatives”)
	1. Include reasons why cases were missed by ESP
8. Number of cases where the ESP classification (e.g., acute vs. chronic, active vs. latent) was incorrect
	1. Include reasons why ESP misclassified these cases
9. Any other findings that should be brought to MDPH’s attention
10. **Documentation for validation of ESP cases against MAVEN**

*Documentation is completed by MDPH staff.*

1. Create a Patient-Level Line List
2. Information that may be helpful to include
3. Reference IDs
	1. ESP ID
	2. MAVEN ID
	3. Patient ID from site’s EMR
4. Date of case identification
5. Reason case was identified in ESP (which criteria did they meet?), if relevant
6. Classification in MAVEN (i.e., acute vs. chronic, active vs. latent), if relevant
7. Notes learned about a case during validation in MAVEN
8. Notes learned about a case during conversations with site or from documented site validation
9. Example of what this table might look like:

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Case Status** | **ESP ID** | **MAVEN ID** | **Pat ID** | **Date Identified** | **ESP Criteria** | **Notes from MAVEN validation** | **Notes from conversation with site** |
| Identified by ESP and in MAVEN | 1234 | 5678 | 9101 | 1/1/2017 | A | N/A | N/A |
| In MAVEN, but revoked | 1112 | 1314 | 1516 | 1/2/2017 | B | Note in MAVEN indicating case was revoked because… | Note in EMR stated…  |
| Not in MAVEN | 1718 | N/A | 2122 | 1/4/2017 | B | Could not find case with name and birth date given | Lab was mismapped, not a case. Mapping has been fixed. |
| In MAVEN, but not identified by ESP | N/A | 2526 | 2728 | 1/6/2017 | A | Confirmatory lab was done a different site | Confirmatory lab not in EMR, so could not be identified by ESP |
| Acute in ESP, but Chronic in MAVEN | 2930 | 3132 | 3334 | 1/15/2017 | C | Teleform/CRF was not returned, so ALT lab identified via ESP was never reported to MAVEN | Site confirmed that this is an acute case |
| Chronic in ESP, but Acute in MAVEN | 3536 | 3738 | 3940 | 1/20/2017 | D | Symptoms were reported on CRF, but not identified by ESP | Site confirmed that this is an acute case |

1. Create a Validation Summary
2. Using the patient-level line list, put together a summary of finding from the validation to share with appropriate ISIS and program staff at MDPH.
3. Number of cases identified
4. Time period in which cases were identified
5. Number of cases identified by ESP that were also in MAVEN (i.e., “true positives”)
6. Number of cases identified by ESP that were not in MAVEN (i.e., “false positives”) or were revoke in MAVEN
	1. Include reasons why cases were identified by ESP
	2. After discussing with site, should these cases have been reported?
7. Number of cases not identified by ESP that were in MAVEN (i.e., “false negatives”)
8. Include reasons why cases were missed by ESP
9. After discussing with site, should these cases have been reported?
10. Number of cases where the ESP classification (e.g., acute vs. chronic, active vs. latent) did not match classification in MAVEN
11. After discussing with site, which classification is correct?
12. Include reasons why cases were misclassified by ESP or by MAVEN
13. Any other findings that should be brought to the attention of ISIS or program staff